Skip to main content

Table 5 Prevalence of intermediate states of hyperglycemia,* baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), n = 15102, 2008-2010

From: High prevalence of diabetes and intermediate hyperglycemia – The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)

 

Total

Men (n = 6885)

Women (n = 8217)

 

n

%

95% CI

n

%

95% CI

n

%

95% CI

IGT

3064

20.3

19.7-20.9

1455

21.1

20.2-22.1

1609

19.6

18.7-20.4

IFG (WHO)

2886

19.1

18.5-19.7

1680

24.4

23.4-25.4

1206

14.7

13.9-15.4

IFG (ADA)

7946

52.6

51.8-53.4

4050

58.8

57.7-60.0

3896

47.4

46.3-48.5

Intermediate HbA 1C (ADA ) **

2431

16.1

15.5-16.7

1011

14.7

13.9-15.5

1420

17.3

16.5-18.1

Intermediate HbA 1C ≥6.0%***

1049

7.0

6.5-7.4

433

6.3

5.7-6.9

616

7.5

6.9-8.1

IFG (WHO) or IGT

4684

31.0

30.3-31.8

2406

35.0

33.8-36.1

2278

27.7

26.8-28.7

IFG (ADA) or IGT

8472

56.1

55.3-56.9

4217

61.3

60.1-62.4

4255

51.8

50.7-52.9

IFG (WHO) or Intermediate HbA 1C (ADA)

4514

29.9

29.2-30.6

2266

32.9

31.8-34.0

2248

27.4

26.4-28.3

IFG (ADA) or Intermediate HbA 1C (ADA)

8532

56.5

55.7-57.3

4210

61.2

60.0-62.3

4322

52.6

51.5-53.7

IGT, IFG (WHO) or Intermediate HbA 1C (ADA)

5929

39.3

38.5-40.0

2852

41.4

40.3-42.6

3077

37.5

36.4-38.5

IGT, IFG (ADA) or Intermediate HbA 1C (ADA)

8971

59.4

58.6-60.2

4356

63.3

62.1-64.4

4615

56.2

55.1-57.2

  1. *After excluding diabetes defined by a self report, medication use or elevated HbA1C, fasting plasma glucose or plasma glucose 2 h after a glucose load.
  2. **HbA1C ≥5.7% (≥38.8 mmol).
  3. ***HbA1C ≥6.0% (≥42.1 mmol).
  4. IGT = impaired glucose tolerance; IFG = impaired fasting glucose; ADA = American Diabetes Association; WHO = World Health Organization; HbA1C = glycated hemoglobin.